Forest Laboratories Articles
Forest Labs' profit slumps 76% on Lexapro patent loss
23 April 2013
Preliminary NICE guidance negative on Pfizer's Xalkori for lung cancer; backs Colobreathe and Tobi Podhaler for CF
27 March 2013
Drugmakers to continue facing growing generic competition in 2013
17 February 2013
Forest Labs posts third-quarter loss, hit by Lexapro sales slump
16 January 2013
Forest in patent settlement with Glenmark; Watson generic Lysteda cleared; and Dr Reddy's debuts generic Propecia
3 January 2013
Forest launches COPD product Tudorza in USA
12 December 2012
Insights on the US Alzheimer's disease market
3 December 2012
Forest Labs files NDA for cariprazine for schizophrenia and bipolar indications; patent settlements
29 November 2012
Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake
24 October 2012
Forest Labs' second fiscal quarter sales and earnings plummet
16 October 2012
Almirall gains rights for IBS drug linaclotide in Mexico
10 September 2012
FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation
3 September 2012
Icahn wins Forest Labs board seat, but only one
16 August 2012
Icahn goes to court, alleging Forest Labs has "poison pill" built into major license accord
13 August 2012
ISS supports Icahn nominees for Forest Labs board
2 August 2012
Forest Labs profit plunges as Lexapro loses patent
18 April 2012
Forest Labs, Gedeon Richter plan 2012 filing for cariprazine
29 February 2012
Almirall looks to robust 2012 despite higher losses
28 February 2012
Forest Labs get EU appro for Colobreathe
27 February 2012
More strong data on Forest and Richter antipsychotic cariprazine
9 February 2012
Forest Labs EPS beat consensus forecasts
18 January 2012
Almirall starts Ph III COPD trial; collaborates with BioFocus; and posts sales and earnings downturn
16 November 2011
US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall
24 October 2011
Forest Lab’s profit slumps nearly 13%, but sales up 9%
19 October 2011
AstraZeneca and Forest initiate Ph III trials of CAZ-AVI
18 October 2011
Forest Labs repurchases $350 million additional shares
16 August 2011
FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER
10 August 2011
Forest Labs 1st-qtr 2011 profit more than doubles
21 July 2011
Positive Ph III results for Forest Labs and Pierre Fabre’s levomilnacipran in major depressive disorder
18 July 2011
Forest and Almirall see early filing of COPD drug aclidinium with US FDA; Appointment at Almirall
4 July 2011
Forest Labs chief to challenge potential action to exclude him from Federal health care programs; completes Clinical Data buy
15 April 2011
Almirall and Forest say their COPD drug aclidinium shows positive results and Ph III and Ph II studies
6 January 2011
Forest acquires Grunenthal’s cystic fibrosis franchise in Europe
22 December 2010
Generic erosion will constrain hospital-acquired infections drug market growth through 2019
14 December 2010
US FDA approves Novartis Afinitor for SEGA, Forest’s Teflaro for CABP and Avanir’s Nuedexta for PBA
1 November 2010
Forest agrees to guilty plea for violating FDA laws and pay over $300 million in penalties
16 September 2010
Almirall/Ironwood’s IBS drug linaclotide shows positive Ph III results
15 September 2010
Nycomed’s US partner Forest Labs responds to FDA complete response letter for Daxas
14 September 2010
Forest/Merz settle with Mylan and others of generic Namenda; Impax’ generic Opana cleared in USA
23 July 2010
Combo Alzheimer's drug that delays nursing home admission would earn higher patient share in the USA than Europe
18 February 2010
Roche enters COPD sector with 400 million-plus-euro deal with Galapagos and antibody accord with AnaptysBio
12 January 2010
Almirall rises on positive Ph III results for aclidinium in COPD, partnered with Forest; Likely FDA “no” to Forests’ Bystolic in CHF
8 January 2010
Germany’s Merz to acquire BioForm Medical for $253 milliion
5 January 2010
Almirall and Forest Labs to expand LAS100977 respiratory deal with $75 million upfront
17 December 2009
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
Ironwood Pharma in deals for linaclotide with Spain’s Almirall and Japan’s Astellas
10 November 2009
AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts
29 October 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Novartis to pay up to $485 million for Paratek’s IV antibiotic
12 October 2009
Zacks analysts view AstraZeneca/Forest deal favorably
18 August 2009
AstraZeneca buys rights to co-develop Forest’s ceftaroline
12 August 2009
Further studies needed for aclidinium bromide
16 March 2009
Lundbeck's 2008 net profit drops 15%
16 March 2009
Forest accused of illegal promotion
9 March 2009
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
